Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

BLUE

Bluebird bio Inc

Apr 17 • 04:00PM ET

0.9633

Dollar change -0.0270
Percentage change -2.73	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN IBB VTWO DFAT IWC ITOT DFAC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.74	Insider Own	1.51%	Shs Outstand	192.74M	Perf Week	-19.05%
Market Cap	185.67M	Forward P/E	-	EPS next Y	-0.88	Insider Trans	-1.31%	Shs Float	189.83M	Perf Month	-33.10%
Income	-91.17M	PEG	-	EPS next Q	-0.44	Inst Own	61.93%	Short Float	15.67%	Perf Quarter	-31.68%
Sales	21.73M	P/S	8.54	EPS this Y	10.88%	Inst Trans	7.50%	Short Ratio	3.43	Perf Half Y	-65.60%
Book/sh	2.08	P/B	0.46	EPS next Y	45.28%	ROA	-16.08%	Short Interest	29.75M	Perf Year	-71.58%
Cash/sh	0.95	P/C	1.01	EPS next 5Y	45.80%	ROE	-47.81%	52W Range	0.88 - 5.53	Perf YTD	-30.20%
Dividend Est.	-	P/FCF	-	EPS past 5Y	15.14%	ROI	-20.06%	52W High	-82.58%	Beta	0.81
Dividend TTM	-	Quick Ratio	1.42	Sales past 5Y	-	Gross Margin	-15.86%	52W Low	9.59%	ATR (14)	0.12
Dividend Ex-Date	-	Current Ratio	1.55	EPS Y/Y TTM	87.79%	Oper. Margin	-1523.91%	RSI (14)	34.16	Volatility	9.40% 8.78%
Employees	-	Debt/Eq	1.36	Sales Y/Y TTM	322.60%	Profit Margin	-419.62%	Recom	2.77	Target Price	3.77
Option/Short	Yes / Yes	LT Debt/Eq	1.04	EPS Q/Q	29.93%	Payout	-	Rel Volume	1.00	Prev Close	0.99
Sales Surprise	-53.53%	EPS Surprise	5.67%	Sales Q/Q	17353.52%	Earnings	Mar 26 BMO	Avg Volume	8.66M	Price	0.96
SMA20	-22.36%	SMA50	-23.52%	SMA200	-62.13%	Trades		Volume	8,692,193	Change	-2.73%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-11-23	Downgrade	HSBC Securities	Hold → Reduce
Dec-08-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$3 → $7
Oct-17-23	Initiated	Cantor Fitzgerald	Neutral
Sep-06-23	Initiated	HSBC Securities	Buy	$4.21
Jul-19-23	Upgrade	BofA Securities	Neutral → Buy	$6 → $10
Jun-01-23	Upgrade	Barclays	Equal Weight → Overweight	$7 → $8
Apr-28-23	Initiated	JP Morgan	Overweight	$7
Mar-07-23	Initiated	Robert W. Baird	Outperform	$10
Aug-05-22	Upgrade	Barclays	Underweight → Equal Weight
Aug-02-22	Upgrade	Raymond James	Mkt Perform → Outperform	$8
Apr-06-22	Downgrade	Cowen	Outperform → Market Perform
Mar-07-22	Downgrade	Barclays	Equal Weight → Underweight	$4
Nov-08-21	Reiterated	Wells Fargo	Equal Weight	$25 → $16
Nov-08-21	Reiterated	Wedbush	Neutral	$22 → $11
Nov-08-21	Reiterated	RBC Capital Mkts	Sector Perform	$26 → $14
Nov-08-21	Reiterated	Canaccord Genuity	Hold	$20 → $15
Nov-08-21	Reiterated	Barclays	Equal Weight	$20 → $13
Nov-08-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$11
Nov-08-21	Downgrade	Goldman	Neutral → Sell	$23 → $10
Aug-10-21	Resumed	William Blair	Mkt Perform

Show Previous Ratings

Apr-16-24 02:05PM	bluebird (BLUE) Underperforms Industry YTD Amid Challenges (Zacks)
Apr-15-24 08:15AM	Is Bluebird Bio Stock a Buy? (Motley Fool) -6.36%
Apr-13-24 04:22PM	Better Buy: Bluebird Bio Vs. Novavax (Motley Fool)
Apr-11-24 08:30AM	Is This Beaten-Down Stock a Good Acquisition Target? (Motley Fool)
08:00AM	bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
11:33AM	Loading…
Apr-02-24 11:33AM	bluebird bio, Inc. (NASDAQ:BLUE) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-29-24 05:20AM	Bluebird Bio Stock Has 138% Upside, According to 1 Wall Street Analyst (Motley Fool)
Mar-27-24 11:37AM	bluebird (BLUE) Misses on Q4 Revenues, Provides Portfolio Updates (Zacks) +13.75%
10:00AM	Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline (Zacks)
Mar-26-24 07:01AM	bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance (Business Wire) -11.76%
Mar-25-24 04:05PM	bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call (Business Wire)
Mar-19-24 07:44AM	bluebird (BLUE) Gets $175 Million Loan From Hercules, Shares Up (Zacks)
Mar-18-24 06:05PM	Why Bluebird Bio Stock Flew Higher Than the Market Today (Motley Fool)
08:00AM	bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital (Business Wire)
Mar-13-24 07:50AM	Is Bluebird Bio Stock a Buy Now? (Motley Fool)
08:00AM	Loading…
Mar-11-24 08:00AM	bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy (Business Wire) -7.33%
Mar-05-24 06:56PM	Why Bluebird Bio Stock Dived Into the Red on Tuesday (Motley Fool) -9.15%
Jan-27-24 07:28AM	If You Invested $1,000 in Bluebird Bio in 2019, This Is How Much You Would Have Today (Motley Fool)
05:27AM	5 Best 52-Week Low Stocks To Buy Now (Insider Monkey)
Jan-10-24 06:55AM	2 Red Flags for Bluebird Bio Stock (Motley Fool)
Jan-08-24 08:00AM	bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook (Business Wire)
Jan-04-24 03:32PM	Bluebirds Plans to Win in Sickle Cell Come Into Focus (The Wall Street Journal) +5.84%
Jan-03-24 07:15AM	Better Risky Investment: Bluebird Bio vs. Shiba Inu (Motley Fool) -6.80%
Jan-02-24 08:00AM	bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +6.52%
Dec-26-23 08:00AM	Should You Invest in Bluebird Bio Right Now? (Motley Fool)
Dec-24-23 07:39AM	If You Invested $10,000 in Bluebird Bio In 2021, This Is How Much You Would Have Today (Motley Fool)
Dec-23-23 07:30AM	1 Green Flag and 1 Red Flag for Bluebird Bio Stock (Motley Fool)
Dec-22-23 08:45AM	3 Money-Saving Tricks for Investing in Biotech Stocks in 2024 (Motley Fool)
Dec-20-23 02:23PM	Bluebird Bio Stock Plunges (Barrons.com) -45.68%
01:54PM	Bluebird Bio Stock Is in Free Fall Weeks After a Landmark FDA Approval. Heres Why. (Barrons.com)
09:41PM	Loading…
Dec-19-23 09:41PM	bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock (Business Wire) -20.33%
Dec-18-23 04:01PM	bluebird bio, Inc. Announces Proposed Public Offering of Common Stock (Business Wire) -6.73%
Dec-15-23 11:14AM	Down 30% in a Week, What in the World Is Going On With Bluebird Bio Stock? (Motley Fool)
Dec-11-23 05:43AM	Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug? (Motley Fool) +7.34%
Dec-10-23 12:02PM	Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels (Business Wire)
Dec-09-23 11:31AM	Long-term Follow-up Data From bluebirds Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events (Business Wire)
Dec-08-23 01:45PM	FDA Approves Worlds First Crispr Gene-Editing Drug for Sickle-Cell Disease (The Wall Street Journal) -40.54%
01:01PM	bluebird bio Details Plans for the Commercial Launch of LYFGENIA Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events (Business Wire)
12:35PM	bluebird bio Announces FDA Approval of LYFGENIA (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events (Business Wire)
Dec-07-23 11:30AM	Bluebird (BLUE) Up 48.2% Since Last Earnings Report: Can It Continue? (Zacks)
08:45AM	These 2 Stocks Could Be About to Soar: Are They Buys? (Motley Fool)
Dec-01-23 07:41AM	bluebird bio (BLUE) Stock Gains 25.6% in a Month: Here's How (Zacks) +11.52%
Nov-29-23 02:28PM	If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names (InvestorPlace)
Nov-26-23 04:44PM	2 Biotech Stocks That Could Soar in December (Motley Fool)
Nov-24-23 07:00AM	Gene Editing Will Change Medicineand Maybe Health Investing Too (The Wall Street Journal)
Nov-08-23 03:39PM	bluebird bio, Inc. (NASDAQ:BLUE) Q3 2023 Earnings Call Transcript (Insider Monkey) -7.91%
Nov-07-23 05:18PM	Why Bluebird Bio Stock Soared 7% Higher on Tuesday (Motley Fool) +7.27%
08:00AM	Bluebird Bio Inc (BLUE) Reports Q3 2023 Financial Results: Strong Commercial Launch and ... (GuruFocus.com)
07:46AM	Bluebird Bio Q3 Loss Narrows, Tops Estimates; Revenues Miss Estimates (RTT News)
07:27AM	Bluebird: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress (Business Wire)
Nov-04-23 08:45AM	Is Bluebird Bio Stock a Buy? (Motley Fool)
Nov-02-23 09:37AM	bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition (Business Wire)
Oct-30-23 08:00AM	bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million (Business Wire)
Oct-24-23 08:00AM	bluebird bio to Host Third Quarter 2023 Financial Results Conference Call (Business Wire)
Oct-17-23 09:47AM	Dollar Tree upgraded, Microsoft initiated: Wall Street's top analyst calls (The Fly)
Sep-29-23 09:00AM	Where Will Bluebird Bio Be in 1 Year? (Motley Fool)
Sep-20-23 07:21AM	Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio (Motley Fool)
Sep-12-23 07:00AM	More Likely to 5x First: Bluebird Bio vs. CRISPR Therapeutics (Motley Fool)
05:14AM	2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street (Motley Fool)
Sep-07-23 11:30AM	Bluebird (BLUE) Up 7.3% Since Last Earnings Report: Can It Continue? (Zacks) -7.11%
Sep-05-23 04:05PM	bluebird bio Announces September Investor Events (Business Wire)
Aug-29-23 05:25AM	Is Bluebird Bio a Bargain Buy in September? (Motley Fool)
Aug-28-23 08:30AM	Wall Street Thinks This Tiny Biotech Company Could Soar Soon (Motley Fool)
Aug-24-23 10:15AM	1 Beaten-Down Growth Stock You'd Regret Not Buying on the Dip, According to Wall Street (Motley Fool)
Aug-16-23 07:00AM	bluebird bio Confirms That FDA Has Communicated That Advisory Committee Meeting Will Not Be Scheduled for lovo-cel Gene Therapy for Sickle Cell Disease (Business Wire)
Aug-08-23 08:25AM	Bluebird Bio (BLUE) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +8.06%
07:18AM	Bluebird: Q2 Earnings Snapshot (AP Finance)
07:00AM	bluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational Progress (Business Wire)
07:00AM	2 Magnificent Growth Stocks I'm Buying Hand Over Fist Right Now (Motley Fool)
Aug-05-23 09:40AM	1 Beaten-Down Stock That Could Soar by 89%, According to Wall Street (Motley Fool)
Jul-27-23 11:19AM	Bank of America Says These 2 Stocks Could Double Your Money Heres Why They Could Rally (TipRanks) -5.81%
Jul-25-23 08:00AM	bluebird bio to Host Second Quarter 2023 Financial Results Conference Call and Provide Commercial Update (Business Wire)
Jul-22-23 06:14AM	3 Small-Cap Stocks That Could Be Big-Time Winners (Motley Fool)
Jul-20-23 01:14AM	4 big analyst picks: AMD called a 'Top Pick' at Wolfe; Cisco upped at JPMorgan (Investing.com)
Jul-19-23 12:36PM	Why Bluebird Bio Stock Is Taking Flight Today (Motley Fool) +16.51%
Jun-30-23 10:15AM	Down 51% in 2023, Here's Why Bluebird Bio Stock Could Soon Double, Says Wall Street (Motley Fool)
Jun-29-23 09:53AM	This 1 Problem Could Sink at Least 4 Gene-Editing Stocks (Motley Fool) -5.01%
07:45AM	Is Bluebird Bio Stock a Buy Now? (Motley Fool)
Jun-21-23 07:00AM	bluebird bio Announces FDA Priority Review of the Biologics License Application for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events (Business Wire)
Jun-15-23 10:00AM	2 Short-Squeeze Candidates That Could Go Parabolic (Motley Fool)
Jun-08-23 11:30AM	Bluebird (BLUE) Down 26% Since Last Earnings Report: Can It Rebound? (Zacks)
Jun-01-23 02:09AM	4 big analyst picks: Avis Budget zooms higher on Deutsche upgrade (Investing.com) +5.67%
May-10-23 07:57AM	Will bluebird bio (NASDAQ:BLUE) Spend Its Cash Wisely? (Simply Wall St.)
May-09-23 07:10AM	Bluebird: Q1 Earnings Snapshot (AP Finance) +12.64%
07:00AM	bluebird bio Reports First Quarter 2023 Financial Results and Highlights Operational Progress (Business Wire)
Apr-27-23 04:05PM	bluebird bio Announces First Quarter 2023 Earnings Date and Upcoming Investor Events (Business Wire)
Apr-24-23 03:49PM	With FDA Submission For Sickle Cell Gene Therapy, Bluebird Bio Can Potentially Have 3 Approved Products By 2023 (Benzinga)
07:30AM	bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events (Business Wire)
Apr-13-23 02:17PM	$2M Price Tag for Sickle Cell Gene Therapies Could Be Cost-Effective Under Certain Scenarios, Finds ICER Analysis (Benzinga) +17.20%
Apr-06-23 10:15AM	Should Investors Buy the Dip With Bluebird Bio Stock? (Motley Fool)
08:00AM	What's the Better Dip to Buy: CRISPR Therapeutics vs. Bluebird Bio (Motley Fool)
06:30AM	Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio (Motley Fool)
Apr-02-23 09:15AM	1 Small-Cap Stock That Could Soar in 2023 (Motley Fool)
Mar-30-23 01:54PM	Why Bluebird Bio Stock Is Sinking This Week (Motley Fool)
Mar-29-23 08:15AM	Bluebird Bio (BLUE) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -24.54%
07:00AM	bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress (Business Wire)
Feb-24-23 10:00AM	Bluebird Bio (BLUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-08-23 08:05AM	1 Beaten-Down Stock That Has a Lot to Prove in 2023 (Motley Fool) -6.73%
Feb-03-23 05:00AM	Here's why 2seventy bio's chief executive thinks 2023 will be a 'special year' (American City Business Journals)

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Obenshain Andrew	President and CEO	Mar 04 '24	Sale	1.53	6,095	9,311	279,998	Mar 05 05:40 PM
Klima Thomas J	See Remarks	Mar 04 '24	Sale	1.53	4,573	6,986	124,840	Mar 05 05:39 PM
Colvin Richard A	Chief Medical Officer	Mar 01 '24	Sale	1.53	6,770	10,342	118,368	Mar 05 05:40 PM
Vittiglio Joseph	Chief Business & Legal Officer	Feb 05 '24	Sale	0.90	5,217	4,708	44,783	Feb 06 04:07 PM
Klima Thomas J	See Remarks	Feb 05 '24	Sale	0.90	2,714	2,449	129,413	Feb 06 04:07 PM
Obenshain Andrew	President and CEO	Feb 05 '24	Sale	0.90	1,879	1,696	286,093	Feb 06 04:07 PM
Obenshain Andrew	President and CEO	Jan 05 '24	Sale	1.43	3,162	4,520	287,972	Jan 09 04:05 PM
Colvin Richard A	Chief Medical Officer	Jan 05 '24	Sale	1.42	597	845	125,138	Jan 09 04:05 PM
Krawtschuk Christopher	Chief Financial Officer	Dec 06 '23	Sale	4.52	4,526	20,437	45,474	Dec 08 04:42 PM
Obenshain Andrew	President and CEO	Nov 03 '23	Sale	3.17	807	2,555	291,134	Nov 03 04:10 PM
Colvin Richard A	Chief Medical Officer	Nov 02 '23	Sale	2.98	2,343	6,975	125,735	Nov 03 04:10 PM
Klima Thomas J	See Remarks	Sep 05 '23	Sale	3.79	922	3,493	132,127	Sep 06 04:30 PM
Obenshain Andrew	President and CEO	Aug 10 '23	Sale	3.54	16,929	59,956	291,941	Aug 10 05:00 PM
Klima Thomas J	See Remarks	Jun 02 '23	Sale	3.50	4,130	14,451	133,049	Jun 06 04:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BLUE

Bluebird bio Inc

Upgrade your FINVIZ experience